Cytokinetics and the ALS Association (ALSA) have announced an expanded partnership to advance support services for ALS patients and caregivers and to increase disease awareness. The partnership, which spans both national and regional levels, will include increased sponsorship of the National Walks to Defeat ALS®, initiatives of the ALSA Golden West Chapter, and a challenge grant for care services for ALS patients in the San Francisco Bay Area. Cytokinetics is the developer of tirasemtiv, an activator of the fast skeletal muscle troponin complex, as a therapy for ALS, and is planning a Phase III trial in ALS based on results from the Phase II trial suggesting the drug improves respiratory muscle function. The partnership with ALSA is an opportunity for the company to expand its support of patient services in parallel to advancing its clinical program.
Click here to read more.Share this: